Retatrutide 6mg
Price range: $ 130.00 through $ 290.00
Retatrutide (6mg) is a novel triple receptor agonist peptide targeting GIP, GLP-1, and glucagon receptors. Designed for advanced metabolic research on weight regulation, energy expenditure, and glycemic control. For laboratory research only.
Revolutionary Triple-Agonist Research: Retatrutide 6mg
Retatrutide represents a paradigm shift in metabolic research. As a first-in-class triple receptor agonist, it simultaneously targets three key metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) , glucagon-like peptide-1 (GLP-1) , and glucagon . This triple-action mechanism distinguishes retatrutide from existing dual-agonist (tirzepatide) and single-agonist (semaglutide) peptides, making it a highly valuable tool for advanced research into obesity, type 2 diabetes mellitus (T2DM), and broader metabolic disorders .
Developed by Eli Lilly and Company, retatrutide is currently in Phase 3 clinical trials (TRIUMPH series) and has demonstrated unprecedented efficacy in preclinical and early clinical studies . For research institutions exploring the next generation of incretin-based therapies, this 6mg lyophilized peptide offers a potent, high-purity compound for in vitro and in vivo investigations.
Why Study Retatrutide?
Obesity and T2DM are global health crises with interconnected pathophysiology involving insulin resistance, dysregulated appetite, and abnormal energy expenditure . Traditional single-agonist peptides address one pathway at a time. Retatrutide’s triple agonism offers a multi-pronged approach:
- GLP-1 Receptor Activation: Enhances glucose-dependent insulin secretion, delays gastric emptying, and promotes satiety via hypothalamic pathways .
- GIP Receptor Activation: Complements GLP-1 by further stimulating insulin secretion and influencing adipose tissue metabolism .
- Glucagon Receptor Activation: Increases energy expenditure, promotes lipolysis, and may directly reduce liver fat content .
Recent Phase 3 data from the TRIUMPH-1 trial demonstrated that retatrutide 12mg produced mean body weight reductions of 28.3% at 80 weeks in adults with obesity (mean BMI 40.0 kg/m²) . In absolute terms, this corresponded to an average loss of 31.9 kg (70.3 lbs) . Furthermore, 45.3% of participants receiving 12mg achieved ≥30% weight loss, and improvements were noted in waist circumference, triglycerides, systolic blood pressure, and hs-CRP .
Product Specifications
| Parameter | Specification |
|---|---|
| Peptide Name | Retatrutide (LY3437943) |
| Quantity | 6mg per vial |
| Mechanism | Triple agonist: GIP, GLP-1, Glucagon receptors |
| Molecular Formula | C₈H₁₄N₁₈O₁₉ (peptide sequence proprietary) |
| Purity | ≥98% by HPLC |
| Form | Lyophilized sterile powder |
| Storage | -20°C (-4°F), lyophilized |
| Reconstitution | Sterile bacteriostatic water or 0.9% NaCl |
| Research Applications | Obesity, T2DM, metabolic syndrome, energy expenditure |
| Legal Status | For laboratory research only — Not for human use |
For research institutions seeking to buy retatrutide for metabolic research, our 6mg vials provide a convenient format for dose-response studies and in vivo protocols. Researchers frequently search for GLP-1 GIP glucagon triple agonist compounds, and retatrutide is the leading investigational molecule in this class. If your lab needs to purchase triple agonist peptides, this compound offers a mechanism of action distinct from tirzepatide for research or semaglutide for laboratory studies.
Many laboratories ask, “Where can I order retatrutide online for preclinical studies?” Our peptide is manufactured under strict quality controls. This retatrutide 6mg vial is ideal for researchers studying appetite suppression pathways, energy homeostasis, and glucose-dependent insulin secretion. Buy research peptides with confidence knowing each batch is HPLC-verified. The retatrutide peptide has been studied in MC4R knockout models, showing 24.1% body weight reduction in preclinical studies .
Mechanism of Action Deep Dive
GIP/GLP-1/Glucagon Receptor Synergy
Retatrutide’s molecular structure enables potent activation of three class B G-protein-coupled receptors (GPCRs). This triple agonism produces distinct and potentially synergistic metabolic effects:
- GLP-1 Pathway: Reduces food intake via central (hypothalamic) and peripheral (gastric emptying) mechanisms. Improves glycemic control through glucose-dependent insulin secretion .
- GIP Pathway: Enhances insulin secretion in the presence of hyperglycemia. May influence adipocyte metabolism and lipid buffering .
- Glucagon Pathway: Increases energy expenditure through hepatic glucose production and thermogenesis. Promotes lipolysis in adipose tissue .
Preclinical studies in MC4R knockout mice (a model of genetic obesity) demonstrated that retatrutide achieved 24.1 ± 5.8% body weight reduction over 21 days, with significant suppression of food intake and improvements in plasma insulin levels, HOMA-IR, cholesterol, and liver enzymes (AST, ALT) .
Comparison with Other Incretin Peptides
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor Targets | GIP, GLP-1, Glucagon | GIP, GLP-1 | GLP-1 |
| Clinical Phase | Phase 3 (TRIUMPH) | Approved (Mounjaro/Zepbound) | Approved (Wegovy/Ozempic) |
| Weight Loss Efficacy (Phase 3) | ~28% at 80 weeks (12mg) | ~21% at 72 weeks (15mg) | ~15% at 68 weeks (2.4mg) |
| Primary Research Applications | Obesity, T2DM, MASLD | Obesity, T2DM | Obesity, T2DM |
| Distinctive Feature | Glucagon-mediated energy expenditure | Dual incretin action | Pure GLP-1 agonism |
Storage & Handling Specifications
| Parameter | Specification |
|---|---|
| Storage Temperature (Lyophilized) | -20°C (-4°F) or lower |
| Light Protection | Yes — store in original container or foil-wrapped |
| Reconstitution Solution | Sterile 0.9% NaCl or bacteriostatic water (0.9% benzyl alcohol) |
| Post-Reconstitution Storage | 2-8°C (refrigerate), use within 30 days |
| Avoid | Freeze-thaw cycles, vortexing, prolonged room temperature exposure |
| Vehicle for In Vivo Studies | Sterile PBS or saline, pH adjusted to 4.0-7.0 |
Frequently Asked Questions (FAQs)
Q: Is retatrutide approved for human use?
A: No. Retatrutide is an investigational compound currently in Phase 3 clinical trials. It has not received marketing authorization from the FDA, MHRA, or EMA . This product is supplied for laboratory research purposes only and is not for human consumption, therapeutic use, or veterinary application.
Q: What is the purity of the Retatrutide 6mg vial?
A: Our retatrutide is ≥98% purity by HPLC, with mass spectrometry verification. A batch-specific Certificate of Analysis (COA) is available upon request, including chromatograms and residual solvent analysis.
Q: What research applications is retatrutide used for?
A: Retatrutide is studied for obesity pharmacotherapy, type 2 diabetes mellitus, metabolic dysfunction-associated steatotic liver disease (MASLD) , energy expenditure regulation, and glucose homeostasis . It is also being investigated in genetic obesity models, including MC4R deficiency .
Q: How does retatrutide differ from tirzepatide (Mounjaro)?
A: Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism —a third mechanism that may enhance energy expenditure and lipolysis beyond the appetite-suppressing effects of GLP-1 and GIP . Preclinical comparisons show retatrutide achieved 24.1% weight reduction vs. 31.6% for tirzepatide in MC4R KO mice .
Q: What is the typical dosing for retatrutide in research protocols?
A: Dosing depends on the model and study design. In rodent studies, doses ranging from 0.05-0.1 mg/kg administered subcutaneously once daily have been used . Researchers should determine appropriate concentrations based on their specific experimental protocols.
Q: Do you provide a Certificate of Analysis (COA)?
A: Yes. Each batch is tested for purity (HPLC), mass confirmation (MS), endotoxin levels (<1.0 EU/mg), and residual solvents. A COA is available upon request with your lot number.
Q: What adverse effects have been reported in retatrutide clinical trials?
A: In clinical studies, the most common adverse events are gastrointestinal (nausea, vomiting, diarrhea) and dose-related. In TRIUMPH-1, nausea occurred in 42.4% of participants receiving 12mg, and vomiting in 25.3% . Dysesthesia (altered sensation) was also reported more frequently with retatrutide than placebo . These findings inform safety monitoring in ongoing trials.
Research Safety & Compliance
This product is supplied for laboratory research purposes only. It is not a pharmaceutical, dietary supplement, or cosmetic. The following restrictions apply:
- Not for human use: Do not administer to humans or animals outside of approved IACUC protocols.
- Not for diagnostic or therapeutic use: No claims are made regarding safety or efficacy in humans.
- Hazard awareness: Use appropriate PPE (gloves, lab coat, safety glasses) during handling. Retatrutide is a potent peptide and should be handled with standard laboratory precautions.
Weight Loss Online Pharmacy complies with all applicable research chemical regulations. By purchasing this product, you confirm that you will use these materials in compliance with local, state, and federal laws governing laboratory research.
Final Word: Advance Your Metabolic Research
The Retatrutide 6mg peptide offers researchers access to a groundbreaking triple agonist with unprecedented preclinical and clinical efficacy data. Whether your laboratory is investigating obesity pathways, type 2 diabetes mechanisms, or energy expenditure regulation, this high-purity compound supports rigorous, reproducible science. Order Retatrutide 6mg for research today and contribute to the next generation of metabolic pharmacotherapy discovery.
| Qty |
1mg ,2mg ,4mg ,8mg ,10mg |
|---|
